LENZ Logo

LENZ Therapeutics, Inc. (LENZ) Stock Forecast & Price Prediction

Live LENZ Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$26.79

+0.81 (3.12%)

12 Month Price Forecast For LENZ

$26.79
Current Price
$736.75M
Market Cap
7 Ratings
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to LENZ Price Forecasts

+68.0%
To High Target of $45.00
+41.8%
To Median Target of $38.00
+34.4%
To Low Target of $36.00

LENZ Price Momentum

+5.1%
1 Week Change
-1.7%
1 Month Change
+870.7%
1 Year Change
-7.2%
Year-to-Date Change
-31.2%
From 52W High of $38.93
+942.4%
From 52W Low of $2.57

๐Ÿค” Considering LENZ Therapeutics (LENZ)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 6, 2025 5:40 PM UTC

LENZ Analyst Ratings & Price Targets

Based on our analysis of 6 Wall Street analysts, LENZ has a consensus that is bullish. The median price target is $38.00, with forecasts ranging from $36.00 to $45.00. Currently, there are 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.

With LENZ currently trading at $26.79, the median price forecast suggests a 41.8% upside. The most optimistic forecast comes from at , projecting a 68.0% upside, while Joseph Catanzaro at Piper Sandler provides the most conservative target, suggesting a 34.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

LENZ Analyst Consensus

7
Buy
0
Hold
0
Sell

LENZ Price Target Range

Low
$36.00
Average
$38.00
High
$45.00
Current: $26.79

Latest LENZ Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for LENZ.

Date Firm Analyst Rating Change Price Target
Nov 7, 2024 HC Wainwright & Co. Matthew Caufield Buy Reiterates $38.00
Sep 27, 2024 Raymond James Gary Nachman Outperform Initiates $37.00
Aug 15, 2024 Piper Sandler Joseph Catanzaro Overweight Maintains $36.00
Aug 15, 2024 HC Wainwright & Co. Matthew Caufield Buy Reiterates $38.00
Aug 12, 2024 HC Wainwright & Co. Matthew Caufield Buy Initiates $38.00
Apr 15, 2024 Leerink Partners Marc Goodman Outperform Initiates $32.00
Apr 15, 2024 William Blair Tim Lugo Outperform Initiates $0.00
Apr 10, 2024 Citigroup Yigal Nochomovitz Buy Initiates $34.00
Mar 27, 2024 Piper Sandler Joseph Catanzaro Overweight Initiates $28.00

Stocks Similar to LENZ Therapeutics, Inc.

The following stocks are similar to LENZ Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

LENZ Therapeutics, Inc. (LENZ) Financial Data

LENZ Therapeutics, Inc. has a market capitalization of $736.75M with a P/E ratio of -9.8x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -41.9%.

Valuation Metrics

Market Cap $736.75M
Enterprise Value $521.22M
P/E Ratio -9.8x
PEG Ratio -11.4x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +29.5%
Current Ratio 28.6x
Debt/Equity 0.7x
ROE -41.9%
ROA -27.0%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) Company Overview

About LENZ Therapeutics, Inc.

What They Do

Develops therapies to improve vision.

Business Model

LENZ Therapeutics operates as a biopharmaceutical company focused on developing therapies for vision improvement. The company generates revenue through the commercialization of its product candidates, which are currently in Phase III clinical trials, indicating a strong potential for market entry and sales.

Additional Information

Based in Del Mar, California, LENZ Therapeutics is working on innovative solutions for presbyopia, a common age-related vision condition, which could position the company favorably in the growing eye care market.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

0

CEO

Mr. Evert B. Schimmelpennink

Country

United States

IPO Year

2024

LENZ Therapeutics, Inc. (LENZ) Latest News & Analysis

LENZ stock latest news image
Quick Summary

LENZ Therapeutics (LENZ) has formed a hammer chart pattern, suggesting support for the stock. This, along with rising earnings estimate revisions, may indicate a potential trend reversal.

Why It Matters

A hammer chart pattern suggests LENZ has found support, signaling potential price reversal, while rising earnings estimates indicate improving fundamentals, making it a stock to watch.

Source: Zacks Investment Research
Market Sentiment: Positive
LENZ stock latest news image
Quick Summary

LENZ Therapeutics (Nasdaq: LENZ) will participate in upcoming investor conferences as it develops a unique aceclidine-based eye drop for presbyopia.

Why It Matters

LENZ Therapeutics' participation in investor conferences signals potential growth and interest in its innovative eye drop, which could attract investment and affect stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
LENZ stock latest news image
Quick Summary

Why It Matters

Source: Zacks Investment Research
Market Sentiment: Positive
LENZ stock latest news image
Quick Summary

LENZ Therapeutics, Inc. (NASDAQ:LENZ) will host its Q3 2024 earnings conference call on November 6, 2024, at 8:30 AM ET, featuring key company executives and analysts.

Why It Matters

The earnings conference call will provide insights into LENZ Therapeutics' financial performance and strategic direction, influencing investor sentiment and potential stock movements.

Source: Seeking Alpha
Market Sentiment: Neutral
LENZ stock latest news image
Quick Summary

Corxel Pharmaceuticals and LENZ Therapeutics announced topline results from the Phase 3 JX07001 trial of LNZ100 for presbyopia in China.

Why It Matters

Topline data from a Phase 3 trial can significantly impact stock prices for Corxel Pharmaceuticals and LENZ Therapeutics, indicating potential market success or setbacks for their treatments.

Source: Benzinga
Market Sentiment: Positive
LENZ stock latest news image
Quick Summary

LNZ100 met its primary endpoint, with 74% of participants showing significant improvement in visual acuity at 3 hours post-treatment compared to the vehicle group.

Why It Matters

The positive efficacy results for LNZ100 suggest strong market potential, likely boosting investor confidence and interest in the companyโ€™s stock and future profitability.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About LENZ Stock

What is LENZ Therapeutics, Inc.'s (LENZ) stock forecast for 2025?

Based on our analysis of 6 Wall Street analysts, LENZ Therapeutics, Inc. (LENZ) has a median price target of $38.00. The highest price target is $45.00 and the lowest is $36.00.

Is LENZ stock a good investment in 2025?

According to current analyst ratings, LENZ has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.79. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for LENZ stock?

Wall Street analysts predict LENZ stock could reach $38.00 in the next 12 months. This represents a 41.8% increase from the current price of $26.79. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is LENZ Therapeutics, Inc.'s business model?

LENZ Therapeutics operates as a biopharmaceutical company focused on developing therapies for vision improvement. The company generates revenue through the commercialization of its product candidates, which are currently in Phase III clinical trials, indicating a strong potential for market entry and sales.

What is the highest forecasted price for LENZ LENZ Therapeutics, Inc.?

The highest price target for LENZ is $45.00 from at , which represents a 68.0% increase from the current price of $26.79.

What is the lowest forecasted price for LENZ LENZ Therapeutics, Inc.?

The lowest price target for LENZ is $36.00 from Joseph Catanzaro at Piper Sandler, which represents a 34.4% increase from the current price of $26.79.

What is the overall LENZ consensus from analysts for LENZ Therapeutics, Inc.?

The overall analyst consensus for LENZ is bullish. Out of 6 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $38.00.

How accurate are LENZ stock price projections?

Stock price projections, including those for LENZ Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.